Pfizer Inc.
PFE
$25.26
-$1.01-3.85%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2023 | 10/01/2023 | 07/02/2023 | 04/02/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 14.25B | 13.23B | 12.73B | 18.28B | 24.29B |
| Total Other Revenue | -- | -- | -- | -- | 2.22B |
| Total Revenue | 14.25B | 13.23B | 12.73B | 18.28B | 24.29B |
| Cost of Revenue | 13.11B | 3.31B | 2.93B | 4.75B | 10.38B |
| Gross Profit | 1.14B | 9.93B | 9.80B | 13.54B | 13.92B |
| SG&A Expenses | 4.11B | 3.11B | 3.33B | 3.28B | 3.85B |
| Depreciation & Amortization | 1.27B | 1.18B | 1.18B | 1.10B | 1.13B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.37B | 10.28B | 10.08B | 11.62B | 18.97B |
| Operating Income | -7.12B | 2.95B | 2.66B | 6.66B | 5.32B |
| Income Before Tax | -4.13B | -3.35B | 2.27B | 6.27B | 5.23B |
| Income Tax Expenses | -795.00M | -964.00M | -71.00M | 715.00M | 230.00M |
| Earnings from Continuing Operations | -3.33B | -2.39B | 2.34B | 5.56B | 5.00B |
| Earnings from Discontinued Operations | -26.00M | 12.00M | -2.00M | 1.00M | 2.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -9.00M | -6.00M | -11.00M | -13.00M | -8.00M |
| Net Income | -3.37B | -2.38B | 2.33B | 5.54B | 4.99B |
| EBIT | -7.12B | 2.95B | 2.66B | 6.66B | 5.32B |
| EBITDA | -5.45B | 4.51B | 4.23B | 8.13B | 6.82B |
| EPS Basic | -0.60 | -0.42 | 0.41 | 0.98 | 0.89 |
| Normalized Basic EPS | -0.73 | 0.35 | 0.34 | 0.80 | 0.65 |
| EPS Diluted | -0.60 | -0.42 | 0.41 | 0.97 | 0.87 |
| Normalized Diluted EPS | -0.73 | 0.35 | 0.34 | 0.79 | 0.64 |
| Average Basic Shares Outstanding | 5.65B | 5.65B | 5.65B | 5.63B | 5.62B |
| Average Diluted Shares Outstanding | 5.65B | 5.65B | 5.71B | 5.73B | 5.74B |
| Dividend Per Share | 0.41 | 0.41 | 0.41 | 0.41 | 0.40 |
| Payout Ratio | -68.71% | -- | 99.48% | 41.55% | 44.95% |
